V. de Précigout

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Cécile Couchoud, Florian Bayer, Carole Ayav et al. · Kidney International · 2020 · 150 citations · Full text

Hemodialysis, Medicine, Covid-19 Pandemic +9

Nutrition and Outcome on Renal Replacement Therapy of Patients with Chronic Renal Failure Treated by a Supplemented Very Low Protein Diet

Michel Aparicio, Philippe Chauveau, V. de Précigout et al. · Journal of the American Society of Nephrology · 2000 · 134 citations

Cardiac Rhythm Disturbances in Hemodialysis Patients

Frédéric Sacher, Laurence Jesel, Claire Borni-Duval et al. · JACC. Clinical electrophysiology · 2017 · 72 citations

Hemodialysis, Heart Failure, Hemodialysis Patients +7